Connect
MJA
MJA

In Other Journals

Ann Gregory
Med J Aust 2003; 179 (7): . || doi: 10.5694/j.1326-5377.2003.tb05601.x
Published online: 6 October 2003

In chronic heart failure, a Lancet commentary advises that patients whose ejection fraction is 40% or less should be prescribed angiotensinreceptor blockers in addition to ACE inhibitors, β-blockers and/or spironolactone.1 Further, angiotensin-receptor β-blockers should be used as an alternative drug in patients with intolerance to ACE inhibitors, and considered in patients whose ejection fraction is more than 40%. The author was commenting on four papers reporting the results of the CHARM — the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity — program.2 CHARM, involving more than 7000 adults with chronic heart failure living in 26 countries including Australia, found that the angiotensinreceptor blocker candesartan reduced cardiovascular deaths and hospital admissions for heart failure.




Correspondence: 

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.